Disorders in high-density metabolism with insulin resistance and chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Metabolic Disorders

Background:

• Cardiovascular risk escalates with declining renal function in chronic kidney disease (CKD).
• Lipoprotein profiles in CKD resemble those in insulin resistance and metabolic syndrome (MS), featuring small dense low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particles.
• High triglyceride levels correlate with reduced HDL levels in both CKD and MS.

Purpose of the Study:

• To investigate the relationship between chronic kidney disease (CKD) and alterations in high-density lipoprotein (HDL) metabolism.
• To explore the role of insulin resistance in the observed HDL abnormalities in CKD patients.

Main Methods:

• Analysis of lipoprotein composition, including LDL and HDL isoforms.
• Assessment of lipid parameters such as triglycerides and cholesterol.
• Evaluation of apolipoprotein A-I (apo A-I) and A-II (apo A-II) levels.
• Investigation of enzymes involved in HDL metabolism, such as lecithin:cholesterol acyltransferase (LCAT) and cholesterol ester transfer protein (CETP).

Main Results:

• CKD is associated with an increased abundance of small dense LDL and HDL particles.
• Decreased levels of apo A-I and apo A-II are observed in CKD due to increased fractional catabolic rate (FCR).
• HDL maturation is impaired in CKD, evidenced by decreased LCAT activity and potentially influenced by CETP activity.

Conclusions:

• CKD significantly alters HDL metabolism, contributing to increased cardiovascular risk.
• The observed HDL abnormalities in CKD share similarities with metabolic syndrome and insulin resistance.
• The precise contribution of insulin resistance versus other pathophysiological mechanisms to HDL metabolism disorders in CKD remains to be elucidated.